Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FPR1 | P21462 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359097 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL28397725 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL3760910 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL259033 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL14748299 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL19585105 | 1.00 | TSHR (0.50) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL2246998 | 0.83 | TSHR (0.45) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL2251994 | 0.83 | TSHR (0.45) | TSHRTP53SLC7A5CYP2C9PDE4A | |
| SCHEMBL25787135 | 0.83 | TP53 (0.43) | TSHRTP53SLC7A5CYP2C9FPR1 | |
| Butyric Acid SCHEMBL16972049 | 0.82 | FFAR3 (0.52) | TSHRPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| CN-117500934-A | Synthesis and use method of beta-hydroxyisovalerate | 萨西亚公司 | 2024-02-02 | — | — | CN | claimed |
| EP-4573553-A1 | QUANTITATIVE AFFINITY ACTIVITY SPECIFIC CELL ENRICHMENT | ABSCI Corporation (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025058962-A1 | HIGH-THROUGHPUT METHODS FOR KINETIC CHARACTERIZATION, QUANTIFYING AND OPTIMIZING ANTIBODIES AND ANTIBODY FRAGMENTS EXPRESSION IN BACTERIA | Absci Corporation (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-4047085-B1 | NOVEL BRANCHED-CHAIN AMINO ACID AMINOTRANSFERASE MUTANT AND LEUCINE PRODUCTION METHOD USING SAME | CJ CHEILJEDANG CORP (KR) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025007767-A1 | ENGINEERING BACTERIUM FOR PRODUCING L-VALINE, CONSTRUCTION METHOD, AND USE | 黑龙江伊品生物科技有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-115038787-B | Novel branched-chain amino acid aminotransferase variant and leucine production method using the same | CJ第一制糖株式会社 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024040020-A1 | QUANTITATIVE AFFINITY ACTIVITY SPECIFIC CELL ENRICHMENT | Absci Corporation (US) | 2024-02-22 | — | — | WO | disclosed |
| CN-117500934-A | Synthesis and use method of beta-hydroxyisovalerate | 萨西亚公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117467551-A | Acid-resistant yeast strain for high yield of L-malic acid, construction method and application thereof | 中国科学院天津工业生物技术研究所 | 2024-01-30 | — | — | CN | disclosed |
| US-20240026397-A1 | MICROORGANISM PRODUCING L-VALINE AND METHOD FOR PRODUCING L-VALINE USING THE SAME | CJ CHEILJEDANG CORPORATION (KR) | 2024-01-25 | — | — | US | disclosed |
| EP-2559753-A1 | Microorganism having enhanced L-valine productivity and method for producing L-valine using the same | CJ CheilJedang Corporation (KR) | 2013-02-20 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1491625-B1 | MUTATED ISOPROPYLMALATE ISOMERASE | KYOWA HAKKO BIO CO LTD (JP) | 2010-07-21 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7445915-B2 | Mutant isopropylmalate isomerase | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-11-04 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20050130276-A1 | Mutated isopropylmalate isomerase | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-06-16 | — | — | US | disclosed |